Sign In
Buy INSM
$106.92
-0.490 (-0.456%)
At Close: Jul 24, 2026
Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
07:00am, Thursday, 23'rd Jul 2026
BRIDGEWATER, N.J., July 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Andra AP fonden Buys 41,670 Shares of Insmed, Inc. $INSM
04:03am, Wednesday, 22'nd Jul 2026
Andra AP fonden lifted its position in shares of Insmed, Inc. (NASDAQ: INSM) by 114.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Com
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
07:58am, Tuesday, 21'st Jul 2026
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks
Billionaire Investor Stanley Druckenmiller's Top 5 Picks: Worth Buying Today?
11:36am, Monday, 20'th Jul 2026
Stanley Druckenmiller doesn't do consensus. The Duquesne Family Office's latest 13F reveals a top-five long book that skips the mega-cap tech herd almost entirely: a Mexican discount grocer, two biote
Bank of New York Mellon Corp Cuts Stake in Insmed, Inc. $INSM
04:27am, Sunday, 19'th Jul 2026
Bank of New York Mellon Corp lessened its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 9.2% during the first quarter, according to the company in its most recent disclosure with the Securities an
Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients Transcript
04:26pm, Thursday, 16'th Jul 2026
Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients Transcript
Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning
02:32pm, Thursday, 16'th Jul 2026
Insmed Incorporated (NASDAQ:INSM) on Thursday reported 12-month results from the ongoing open-label extension (OLE) study of its once-daily treprostinil palmitil inhalation powder (TPIP) in pulmonary
Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study
11:05am, Thursday, 16'th Jul 2026
Insmed NASDAQ: INSM reported 12-month results from an ongoing open-label extension study of TPIP in patients with pulmonary arterial hypertension, saying the data showed sustained efficacy measures an
– 12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0– –Placebo Crossed Group Demons
Carillon Eagle Mid Cap Growth Fund Q2 2026 Portfolio Review
08:53am, Tuesday, 14'th Jul 2026
Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions. Top secur
Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
07:00am, Tuesday, 23'rd Jun 2026
BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
The Qs Shift Gears: Nasdaq 100 Rebalances While SpaceX Looms
02:19pm, Monday, 22'nd Jun 2026
The Nasdaq 100 implemented its June quarterly rebalance, which shifts the tide for “the Qs.” Namely, the Invesco QQQ Trust (QQQ) and its cost-efficient sibling, the Invesco Nasdaq 100 ETF (QQQM).
Insmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong Buy
07:30am, Monday, 22'nd Jun 2026
Insmed is maintained at "Strong Buy" due to robust pipeline progress and expanding commercial execution. INSM's key catalysts include ARIKAYCE's sNDA submission for 1st-line MAC Lung Disease in H2 202
